{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:34:23Z","timestamp":1781897663483,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>\nMalignant melanoma is among the tumours with the highest increase in incidence of solid tumours in Germany. While most patients are diagnosed at an early stage and show a good prognosis, advanced stages of malignant melanoma are accompanied with a poor prognosis and limited treatment options. Comparable to other tumour entities, the resection of visceral metastases could lead to a better prognosis. Supplementary, the subgroup of oligometastatic patients might benefit from surgical therapy to a greater extent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study analysed 351 patients treated between 2006 and 2017 at the University Hospital of Cologne. A total of 121 patients showed visceral metastases, with which we compared patients with a diffuse tumour spread to patients in an oligometastatic state. Furthermore, we evaluated the effect of visceral resection of oligometastatic, malignant melanoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our analysis showed that patients with an oligometastatic malignant melanoma had a significantly better prognosis than patients with a diffuse pattern of metastases, if they showed visceral metastases. Furthermore, the resection of visceral metastases leads to a significant gain in median overall survival time (13.6 vs. 34.2\u00a0months) and in progression-free survival (9.6 vs. 3.8\u00a0months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The resection of visceral metastases is a rational treatment option in advanced malignant melanoma. Although our study is limited by a small cohort of patients (<jats:italic>n<\/jats:italic>\u2009=\u200918), we believe that the resection of visceral metastases will be fundamental in the treatment of malignant melanoma. In particular, patients in an oligometastatic stage could be an eligible group for surgical treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00423-023-02804-9","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T06:04:31Z","timestamp":1674281071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis"],"prefix":"10.1007","volume":"408","author":[{"given":"Alexander","family":"Urbanski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Minnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kreuzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk L.","family":"Stippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"2804_CR1","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1002\/cncr.26111","volume":"117","author":"JA Sosman","year":"2011","unstructured":"Sosman JA, Moon J, Tuthill RJ et al (2011) A phase 2 trial of complete resection for stage IV melanoma. Cancer 117:4740\u20134746. https:\/\/doi.org\/10.1002\/cncr.26111","journal-title":"Cancer"},{"key":"2804_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"2804_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ddg.13247","volume":"15","author":"TK Eigentler","year":"2017","unstructured":"Eigentler TK, M\u00fchlenbein C, Follmann M et al (2017) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms \u2013 Update 2015\/2016, Kurzversion 2.0. JDDG - J Ger Soc Dermatology 15:e1\u2013e41. https:\/\/doi.org\/10.1111\/ddg.13247","journal-title":"JDDG - J Ger Soc Dermatology"},{"key":"2804_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Gershenwald JE (2018) The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system implications for melanoma treatment and care. Expert Rev Anticancer Ther 18:775\u2013784. https:\/\/doi.org\/10.1080\/14737140.2018.1489246","journal-title":"Expert Rev Anticancer Ther"},{"key":"2804_CR5","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199\u20136206. https:\/\/doi.org\/10.1200\/JCO.2009.23.4799","journal-title":"J Clin Oncol"},{"key":"2804_CR6","unstructured":"Eigentler T, M\u00fchlenbein C, Garbe C, Schadendorf D (2016) S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms. Version 2.:1\u2013241"},{"key":"2804_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.jid.5700026","volume":"126","author":"VK Goel","year":"2006","unstructured":"Goel VK, Lazar AJF, Warneke CL et al (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126:154\u2013160. https:\/\/doi.org\/10.1038\/sj.jid.5700026","journal-title":"J Invest Dermatol"},{"key":"2804_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/CMR.0000000000000127","volume":"25","author":"RM Anforth","year":"2015","unstructured":"Anforth RM, Carlos GRM, Scolyer RA et al (2015) Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Res 25:91\u201394. https:\/\/doi.org\/10.1097\/CMR.0000000000000127","journal-title":"Melanoma Res"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"2804_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","volume":"29","author":"EM Hersh","year":"2011","unstructured":"Hersh EM, O\u2019Day SJ, Powderly J et al (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma. Invest New Drugs 29:489\u2013498. https:\/\/doi.org\/10.1007\/s10637-009-9376-8","journal-title":"Invest New Drugs"},{"key":"2804_CR11","doi-asserted-by":"publisher","first-page":"S1173","DOI":"10.1016\/j.annonc.2020.08.2274","volume":"31","author":"AMA Fernandez","year":"2020","unstructured":"Fernandez AMA, O\u2019Day SJ, de la Merino LC et al (2020) LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004. Ann Oncol 31:S1173. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2274","journal-title":"Ann Oncol"},{"key":"2804_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5269062","volume":"2019","author":"A Rogiers","year":"2019","unstructured":"Rogiers A, Boekhout A, Schwarze JK et al (2019) Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol 2019:1\u201317. https:\/\/doi.org\/10.1155\/2019\/5269062","journal-title":"J Oncol"},{"key":"2804_CR13","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","volume":"26","author":"EM Hersh","year":"2015","unstructured":"Hersh EM, Del Vecchio M, Brown MP et al (2015) A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol 26:2267\u20132274. https:\/\/doi.org\/10.1093\/annonc\/mdv324","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","volume":"43","author":"C Franklin","year":"2017","unstructured":"Franklin C, Livingstone E, Roesch A et al (2017) Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol 43:604\u2013611","journal-title":"Eur J Surg Oncol"},{"key":"2804_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","volume":"44","author":"MH Seegenschmiedt","year":"1999","unstructured":"Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44:607\u2013618. https:\/\/doi.org\/10.1016\/S0360-3016(99)00066-8","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2804_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1258\/jrsm.2011.110279","volume":"105","author":"T Treasure","year":"2012","unstructured":"Treasure T (2012) Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity? J R Soc Med 105:242\u2013246. https:\/\/doi.org\/10.1258\/jrsm.2011.110279","journal-title":"J R Soc Med"},{"key":"2804_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s11605-006-0061-3","volume":"11","author":"TM Pawlik","year":"2007","unstructured":"Pawlik TM, Choti MA (2007) Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 11:1057\u20131077. https:\/\/doi.org\/10.1007\/s11605-006-0061-3","journal-title":"J Gastrointest Surg"},{"key":"2804_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","volume":"235","author":"MA Choti","year":"2002","unstructured":"Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759\u2013766. https:\/\/doi.org\/10.1097\/00000658-200206000-00002","journal-title":"Ann Surg"},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Long GV, Stroiakovski D et al (2017) Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 82:45\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.033","journal-title":"Eur J Cancer"},{"key":"2804_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg"},{"key":"2804_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3238\/arztebl.2016.0597","volume":"113","author":"O Kuss","year":"2016","unstructured":"Kuss O, Blettner M, B\u00f6rgermann J (2016) Propensity score: an alternative method of analyzing treatment effects. Dtsch Arztebl Int 113:597\u2013603. https:\/\/doi.org\/10.3238\/arztebl.2016.0597","journal-title":"Dtsch Arztebl Int"},{"key":"2804_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC (2014) The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33:1242\u20131258. https:\/\/doi.org\/10.1002\/sim.5984","journal-title":"Stat Med"},{"key":"2804_CR23","first-page":"81","volume":"10","author":"ML Lee","year":"2000","unstructured":"Lee ML, Tomsu K, Von Eschen KB (2000) Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 10:81\u201392","journal-title":"Melanoma Res"},{"key":"2804_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/jso.20303","volume":"94","author":"SE Young","year":"2006","unstructured":"Young SE, Martinez SR, Essner R (2006) The role of surgery in treatment of stage IV melanoma. J Surg Oncol 94:344\u2013351. https:\/\/doi.org\/10.1002\/jso.20303","journal-title":"J Surg Oncol"},{"key":"2804_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00008390-200204000-00010","volume":"12","author":"I Panagiotou","year":"2002","unstructured":"Panagiotou I, Brountzos EN, Bafaloukos D et al (2002) Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Res 12:169\u2013173. https:\/\/doi.org\/10.1097\/00008390-200204000-00010","journal-title":"Melanoma Res"},{"key":"2804_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/BF00308624","volume":"19","author":"P Hermanek","year":"1995","unstructured":"Hermanek P (1995) pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J Surg 19:184\u2013190. https:\/\/doi.org\/10.1007\/BF00308624","journal-title":"World J Surg"},{"key":"2804_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","volume":"175","author":"M Angelova","year":"2018","unstructured":"Angelova M, Mlecnik B, Vasaturo A et al (2018) Evolution of metastases in space and time under immune selection. Cell 175:751-765.e16. https:\/\/doi.org\/10.1016\/j.cell.2018.09.018","journal-title":"Cell"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-023-02804-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-023-02804-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-023-02804-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:17:38Z","timestamp":1705594658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-023-02804-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1007\/s00423-023-02804-9","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"4 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the local Ethics Committee of the University of Cologne in view of the retrospective nature of the study, and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the data was obtained retrospectively. The patients treated at our university hospital are informed about the general possibility of utilisation of anonymous data for research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"53"}}